Max von Kleist

5.2k total citations · 1 hit paper
79 papers, 1.2k citations indexed

About

Max von Kleist is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Max von Kleist has authored 79 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Infectious Diseases, 26 papers in Virology and 19 papers in Molecular Biology. Recurrent topics in Max von Kleist's work include HIV Research and Treatment (26 papers), HIV/AIDS Research and Interventions (24 papers) and HIV/AIDS drug development and treatment (22 papers). Max von Kleist is often cited by papers focused on HIV Research and Treatment (26 papers), HIV/AIDS Research and Interventions (24 papers) and HIV/AIDS drug development and treatment (22 papers). Max von Kleist collaborates with scholars based in Germany, United States and France. Max von Kleist's co-authors include Christof Schütte, Wilhelm Huisinga, Redmond P. Smyth, Barbara Rath, Stephan Menz, Djin‐Ye Oh, Roland Marquet, Susanne Duwe, David Katzenstein and Richard A. Oberhelman and has published in prestigious journals such as Nature, Science and Nucleic Acids Research.

In The Last Decade

Max von Kleist

76 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SARS-CoV-2 evolution on a dynamic immune landscape

2025 17 citations Daniela Börnigen, Djin‐Ye Oh et al. Nature profile →

Peers

Countries citing papers authored by Max von Kleist

Since Specialization

Citations

This map shows the geographic impact of Max von Kleist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max von Kleist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max von Kleist more than expected).

Fields of papers citing papers by Max von Kleist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max von Kleist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max von Kleist. The network helps show where Max von Kleist may publish in the future.

Co-authorship network of co-authors of Max von Kleist

This figure shows the co-authorship network connecting the top 25 collaborators of Max von Kleist. A scholar is included among the top collaborators of Max von Kleist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max von Kleist. Max von Kleist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Atypical Influenza A(H3N2) Activity Patterns in Germany, 2021–2023, and Characterization of Newly Emerged Virus Clades 2025 ·Journal of Medical Virology ·Susanne Duwe, Djin‐Ye Oh, Marianne Wedde, Daniela Börnigen, Ralf Ignatius, Max von Kleist, Janine Reiche, Barbara Biere, Thorsten Wolff, Ralf Dürrwald	0
2	Augmentation of wastewater-based epidemiology with machine learning to support global health surveillance 2025 ·Nature Water ·(unknown), (unknown), Hugues Richard, Matthew J. Wade, Shelesh Agrawal, Fabian Amman, Sindy Böttcher, Susanne Lackner, Markus Landthaler, (unknown), (unknown), Fotis Psomopoulos, (unknown), (unknown), Alexander Ullrich, Max von Kleist, Emanuel Wyler, Martin Hölzer, Christopher Irrgang	2
3	SARS-CoV-2 evolution on a dynamic immune landscape breakdown → 2025 ·Nature ·(unknown), (unknown), Daniela Börnigen, (unknown), Djin‐Ye Oh, Matthias Budt, Christin Mache, Claudia Schillings, Stephan Fuchs, Ralf Dürrwald, Thorsten Wolff, Martin Hölzer, Sofia Paraskevopoulou, Max von Kleist	17
4	MoDorado: enhanced detection of tRNA modifications in nanopore sequencing by off-label use of modification callers 2025 ·Nucleic Acids Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Michael Piechotta, Christoph Dieterich, Max von Kleist, Ann E. Ehrenhofer‐Murray	1
5	Sequencing accuracy and systematic errors of nanopore direct RNA sequencing 2024 ·BMC Genomics ·(unknown), (unknown), Patrick Bohn, Martin Hölzer, Redmond P. Smyth, Max von Kleist	34
6	Stochastic Simulation Algorithm For Effective Spreading Dynamics On Time-Evolving Adaptive NetworX (SSATAN-X) 2022 ·Mathematical Modelling of Natural Phenomena ·(unknown), Junyu Wang, Max von Kleist	4
7	Short- and long-range interactions in the HIV-1 5′ UTR regulate genome dimerization and packaging 2022 ·Nature Structural & Molecular Biology ·Liqing Ye, (unknown), Patrick Bohn, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Neva Caliskan, Max von Kleist, Redmond P. Smyth	22
8	Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020 2021 ·Nature Communications ·(unknown), (unknown), (unknown), (unknown), Denise Kühnert, Max von Kleist	15
9	Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany 2021 ·Viruses ·Sébastien Calvignac‐Spencer, Matthias Budt, Matthew R. Huska, Hugues Richard, (unknown), Linus Grabenhenrich, Torsten Semmler, Max von Kleist, Stefan Kröger, Thorsten Wolff, Martin Hölzer	5
10	Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data 2021 ·The Lancet Regional Health - Europe ·Djin‐Ye Oh, Silke Buda, Barbara Biere, Janine Reiche, Frank Schlosser, Susanne Duwe, Marianne Wedde, Max von Kleist, Martin Mielke, Thorsten Wolff, Ralf Dürrwald	103
11	Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes 2021 ·PLoS Computational Biology ·(unknown), (unknown), Max von Kleist	4
12	Brain connectivity inversely scales with developmental temperature in Drosophila 2021 ·Cell Reports ·Ferdi Rıdvan Kiral, (unknown), Gerit Arne Linneweber, (unknown), (unknown), Carsten Duch, Max von Kleist, Bassem A. Hassan, P. Robin Hiesinger	23
13	Local c-di-GMP Signaling in the Control of Synthesis of the E. coli Biofilm Exopolysaccharide pEtN-Cellulose 2020 ·Journal of Molecular Biology ·Anja Richter, Alexandra Possling, (unknown), (unknown), (unknown), Max von Kleist, Regine Hengge	47
14	Discerning the spatio-temporal disease patterns of surgically induced OA mouse models 2019 ·PLoS ONE ·Tobias Haase, (unknown), Benjamin Kohl, Carola Meier, (unknown), Jessica Becker, (unknown), Max von Kleist, Wolfgang Ertel	13
15	The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis 2019 ·Frontiers in Pharmacology ·(unknown), (unknown), Laura Dickinson, Saye Khoo, Max von Kleist	12
16	In silico cytotoxicity assessment on cultured rat intestinal cells deduced from cellular impedance measurements 2017 ·Toxicology in Vitro ·P. P. Gupta, (unknown), Ralf Einspanier, Christof Schütte, Max von Kleist, Jutta Sharbati	2
17	Logical-continuous modelling of post-translationally regulated bistability of curli fiber expression in Escherichia coli 2015 ·BMC Systems Biology ·(unknown), (unknown), Christof Schütte, Heike Siebert, Regine Hengge, Max von Kleist	11
18	Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care 2014 ·PLoS ONE ·Xi Chen, (unknown), Susanne Duwe, (unknown), Sandeep Grover, (unknown), Patrick Obermeier, (unknown), (unknown), Lea Seeber, Max von Kleist, Brunhilde Schweiger, Barbara Rath	13
19	Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis 2013 ·BMC Infectious Diseases ·Barbara Rath, Max von Kleist, María E. Castillo, Lenka Kolevic, Patricia Caballero, Giselle Soto-Castellares, Angela M. Amedee, James E. Robinson, David Katzenstein, Russell B. Van Dyke, Richard A. Oberhelman	120
20	Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV 2010 ·PLoS Computational Biology ·Max von Kleist, Stephan Menz, Wilhelm Huisinga	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact